These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 34710675)

  • 1. Accelerated brain aging in major depressive disorder and antidepressant treatment response: A CAN-BIND report.
    Ballester PL; Suh JS; Nogovitsyn N; Hassel S; Strother SC; Arnott SR; Minuzzi L; Sassi RB; Lam RW; Milev R; Müller DJ; Taylor VH; Kennedy SH; Frey BN;
    Neuroimage Clin; 2021; 32():102864. PubMed ID: 34710675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
    Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
    J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
    Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
    CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
    Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
    Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
    Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
    Diep C; Rosenek N; Khoo Y; Gandhi W; van Reekum CM; Ravindran AV; Ladha KS; Frey BN; Milev RV; Rotzinger S; Lam RW; Kennedy SH; Lou W; Salomons T; Bhat V
    Psychiatry Res; 2022 Jun; 312():114557. PubMed ID: 35461118
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of symptom severity on efficacy and safety of aripiprazole adjunctive to antidepressant monotherapy in major depressive disorder: a pooled analysis.
    Stewart TD; Hatch A; Largay K; Sheehan JJ; Marler SV; Berman RM; Nelson JC
    J Affect Disord; 2014 Jun; 162():20-5. PubMed ID: 24766999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
    Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
    Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
    Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.
    Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V
    J Psychopharmacol; 2022 May; 36(5):604-613. PubMed ID: 35546043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
    Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
    Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
    Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
    J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
    Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
    J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled study.
    El-Khalili N; Joyce M; Atkinson S; Buynak RJ; Datto C; Lindgren P; Eriksson H
    Int J Neuropsychopharmacol; 2010 Aug; 13(7):917-32. PubMed ID: 20175941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis.
    Steffens DC; Nelson JC; Eudicone JM; Andersson C; Yang H; Tran QV; Forbes RA; Carlson BX; Berman RM
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):564-72. PubMed ID: 20827794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.